• Mashup Score: 0
    Optimizing initial therapy of CLL - 2 month(s) ago

    Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the specific considerations for optimizing chronic lymphocytic leukemia (CLL) treatment in patients in the frontline setting. These include age, comorbidities, length of treatment (time-limited or continuous), and access to lines of therapy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      🎥 @DrMDavids of @DanaFarber shares insights into optimizing CLL therapy for patients in the front-line setting - a hot topic at this year’s #iwCLL2023 meeting! Check it out here: 👉https://t.co/CAsNBSmvUL #CLLsm #HemOnc @iwCLL #LeuSM

  • Mashup Score: 0
    Non-Malignant Blood Disorders | VJHemOnc - 2 month(s) ago

    Explore the latest updates and expert interviews in non-malignant blood disorders on The Non-Malignant Channel by VJHemOnc

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      You may have noticed our logo has changed... 👀🩸 We now have a Non-Malignant Channel! We are committed to providing you with comprehensive insights into #blooddisorders, from #cancers to #nonmalignant conditions 🔬 👉 https://t.co/DCGCNNnXP8 Our regular #HemOnc content will… https://t.co/zZS7eLlMsS https://t.co/HvYGWi1s0S

  • Mashup Score: 0
    Insights into mass spectrometry-based proteomics in multiple myeloma research - 2 month(s) ago

    Arun Wiita, PhD, University of California, San Francisco, CA, shares some insights into the use of mass spectrometry-based proteomics in multiple myeloma, highlighting the value of this novel approach in improving research in the field. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #IMS23 | @apwiita of @UCSF shares some insights into the value of mass spectrometry-based proteomics in multiple myeloma. Watch his interview here: 🎥 https://t.co/QMiPor6pOR @Myeloma_Society #MMsm #HemOnc

  • Mashup Score: 2
    Clinical guidance for the use of bispecific antibodies in NHL - 2 month(s) ago

    In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the unique toxicity profile associated with bispecific antibodies and provides guidance for physicians treating patients with non-Hodgkin lymphoma (NHL) using this class of agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      We recently spoke w/ Jason Westin (@Lymphoma_Doc; @MDAndersonNews), who provided clinical guidance for the use of bispecific antibodies in NHL: 🎥 https://t.co/S1PCnzbNQr #LymSM #HemOnc #ImmunoOnc #SOHO23

  • Mashup Score: 0
    Socioeconomic and racial disparities in myeloma trial recruitment - 2 month(s) ago

    Amrutha Sridhar, MBBS, University College London Hospitals, London, UK, discusses how socioeconomic and racial inequalities persist during the enrollment process in multiple myeloma clinical trials. Patients from a lower socioeconomic background are underrepresented in clinical trials, and will have worse overall survival, even after receiving treatment. Gaps in outcomes are additionally more pronounced in older patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #IMS23 | Amrutha Sridhar of @uclh discusses socioeconomic and racial disparities in myeloma trial recruitment. Watch here: 🎥 https://t.co/qjJ1tYQwT7 @Myeloma_Society #MMsm #HemOnc

  • Mashup Score: 0
    iwCLL 2023 | VJHemOnc - 2 month(s) ago

    The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be held in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over the world to discuss the latest updates in the pathobiology and treatment of CLL. The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be hel d in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Missed out on #iwCLL2023? Don't worry, we've got you covered! Our expert interviews can be found here: 🎥 https://t.co/OxDAnUzcHq #CLLsm #LeuSM #HemOnc @iwCLL https://t.co/gBpsqaitpT

Load More